Crucell is a fully integrated biopharmaceutical company. We focus on developing, producing and marketing products that combat infectious diseases. We are the largest independent vaccine company in the world.

Headquartered in Leiden, The Netherlands, Crucell currently employs about 1100 people and has subsidiaries in Switzerland, Spain, Sweden, Italy, Korea and the United States. Crucell N.V. is listed on Euronext and NASDAQ (CRXL) and the SWX Swiss Exchange (CRX). At Crucell, we’re bringing innovation to global health.

Our vaccine business provides stable and predictable sales and cash flow. We sold more than 100 million vaccine doses in over 80 countries throughout the world, which makes us the largest independent vaccine player. Within vaccines we operate in three main markets: paediatric, travel and endemic, and respiratory.

Paediatric:

• Quinvaxem^® - Fully liquid vaccine for protection against five childhood diseases
• Hepavax-Gene^® - Recombinant hepatitis B vaccine
• MoRu-Viraten^® - Vaccine for protection against measles and rubella (all age groups)
• Epaxal® Junior - Low dosage unique aluminum-free hepatitis A vaccine (0.25ml)

Travel and endemic:

• Epaxal^® - Aluminum-free hepatitis A vaccine
• Vivotif^® - Oral typhoid vaccine
• Dukoral^® - Internationally licensed oral vaccine with documented efficacy against diarrhea caused by cholera

Respiratory:

• Inflexal^® V – Virosomal adjuvanted influenza (all age groups)

Crucell has a broad development pipeline, including vaccines and antibody products. Several Crucell products are based on our unique PER.C6^® production technology. Crucell licenses this and other cutting edge technologies to the biopharmaceutical industry. Important partners and licensees are DSM Biologics, Novartis, sanofi aventis, MedImmune, GSK, CSL, Merck and Wyeth.

Valuable Products 

Innovative Technology

Solid Financial Position

Strong Management